Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel Round Funding. The round was led by Qianhai Triwise International Capital Management Co., Ltd., National Medical Equipment Development (NMED) Innovation Center, JenKem Technology Co., Ltd. (SHA: 688356), and Dalton Venture, with exclusive financial advisory services provided by Dingqi Consulting. The funds will be used to advance the clinical trials of the company’s core pipeline and accelerate the technical development and expansion of the iSus® sustained-release platform.
iSus® Platform: Core Technology and Applications
Established in 2021, Raytone Bio focuses on ocular degradable long-acting sustained-release technology, aiming to address the pain point of frequent dosing in eye drop formulations. The company’s core platform technology, iSus®, enables drug delivery over several days to months with a single administration in both the anterior and posterior segments of the eye. This technology significantly improves patient compliance and treatment outcomes.
Technical Breakthroughs and Future Prospects
Over the past three years, the Raytone Bio team has overcome multiple core technical challenges, including formulation processes, degradation cycle control, and automated mass production. The successful development of the iSus® degradable long-acting sustained-release technology platform positions the company to meet the long-term drug release needs in both human and veterinary ophthalmology.
Strategic Implications
The completion of the Angel Round Funding is a significant milestone for Raytone Bio, highlighting the confidence of investors in the company’s innovative approach to ocular drug delivery. By securing this funding, Raytone Bio is well-positioned to accelerate the development of its iSus® platform and contribute to the advancement of sustained-release drug delivery in ophthalmology. This strategic move is expected to enhance the company’s market presence and improve patient care in the treatment of eye diseases.-Fineline Info & Tech
Leave a Reply